All In Biotech

NDA 020839 · Sanofi Aventis US

Plavix

Clopidogrel Bisulfate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Sep 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Nov 17, 1997

Approved uses

4

Original approval plus efficacy supplements

Registered trials

959

224 Phase 3, 102 recruiting

FAERS reports

199,047

161,504 serious, 21,942 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE See full prescribing information for complete boxed warning. Effectiveness of Plavix depends on conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. ( 5.1 , 12.3 ) Tests are available to identify patients who are CYP2C19 poor metabolizers. ( 12.5 ) Consider use of another platelet P2Y 12 inhibitor in patients identified as CYP2C19 poor metabolizers. ( 5.1 ) The effectiveness of Plavix results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1) , Clinical Pharmacology (12.3) ] . Plavix at recommended doses...

What it is approved for

From the label in effect May 30, 2025.

Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), Plavix has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) – For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Plavix is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Plavix should be administered in conjunction with aspirin. Plavix is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Plavix should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke Plavix is indicated to reduce the rate of MI and stroke.

Mechanism: Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y 12 class of ADP receptors on platelets.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PLAVIX · CLOPIDOGREL BISULFATE EQ 300MG BASE · TABLET, ORAL · Prescription · TE AB
  • PLAVIX · CLOPIDOGREL BISULFATE EQ 75MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Clopidogrel Bisulfate" as an intervention, any sponsor and status, largest first.

All 959 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea10,292
  • myocardial infarction9,569
  • fatigue8,828
  • gastrointestinal haemorrhage8,322
  • nausea8,152
  • dizziness7,985
  • diarrhoea7,688
  • drug ineffective7,524
  • asthenia6,927
  • fall6,765
  • cerebrovascular accident6,585
  • death6,241

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,547
20053,480
20064,504
20074,198
20085,010
20096,078
20107,650
20117,642
20128,311
20137,180
201416,070
201511,834
201612,873
201711,625
201814,724
201915,471
202012,377
20219,944
20228,132
20237,597
20247,803
20258,128
20265,864

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Plavix (Clopidogrel Bisulfate)

2024 spending

$6.2M

Beneficiaries

3,054

12,338 claims

Per beneficiary

$2,033

$7.87 per unit

View as table
YearSpending
2020$2,672,448
2021$7,990,526
2022$7,671,667
2023$7,228,749
2024$6,208,363

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 62 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.